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Cell and tissue homeostasisAging is characterized by the general decline in tissue and body function and the increased susceptibility to
age-related pathologies, such as cancer. To maintain optimal tissue and body function, organisms have
developed complex mechanisms for tissue homeostasis. Importantly, it is becoming apparent that these same
mechanisms when deregulated also result in the development of age-related disease. The build in failsafe
mechanisms of homeostasis, which prevent skewing toward disease, themselves contribute to aspects of
aging. Thus, longevity is limited by an intrinsic trade-off between optimal tissue function and disease.
Consequently, aging and age-related diseases, such as cancer and diabetes are driven by the same genetic
determinants. Illustrative in this respect is the insulin/IGF-1 signaling pathway acting through PI3K/PKB and
FOXO. Loss of PKB signaling contributes to diabetes, whereas gain of function of PKB drives cancer. Enhanced
FOXO activity, at least in model organism contributes to extended lifespan and acts as a tumor suppressive
mechanism. Here, we focus on the linkage between PKB and FOXO as a central switch in contributing to tissue
homeostasis and age-related diseases in particular cancer. This article is part of a Special Issue entitled: P13K-
AKT-FoxO axis in cancer and aging.-AKT-FoxO axis in cancer and
.T. Burgering).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Aging is considered the result of deterioration of the body due to
progressive loss of tissue function and integrity. Tissue homeostasis
entails renewal as well as maintenance of cells within the tissues, the
importance of which of these particular processes is dependent on the
particular tissue. While renewal is the result of both proliferation of
(stem) cells, as well as eradication of differentiated cells, maintenance
involves the turnover of cellular constituents themselves. It is
estimated that the human body yearly eradicate and generate a
number of cells that has a mass that is almost equal to that of our body
[1]. To maintain tissue and body integrity, the processes of eradication
and generationmust be tightly controlled.While these processes have
been studied intensively, their crosstalk – the actual homeostasis – is
poorly understood. In addition, cell renewal is thought to occur in
many more tissues than previously appreciated but the extent of cell
turnover varies greatly among different tissues [2]. One of the
prominent pathways involved in turnover of cellular constituents is
autophagy. In particular, macroautophagy and chaperone-mediated
autophagy are responsible for regular removal of cellular constituents
and organelles [3]. Aging is accompanied by the accumulationdamaged constituents and organelles, as well as reduced regenerative
capacity and renewal of tissues. Several cell intrinsic mechanisms
have been proposed to underlie the decline in tissue homeostasis. A
long standing hypothesis is based on the observations of Hayﬂick [4].
Due to the nature of DNA replicating enzymes, telomeres become
shorter with each successive round of replication. After a number of
replications, telomeres become critically short and this results in
permanent withdrawal from the cell cycle. In some cells such as the
germline cells, this is counteracted by the activity of telomerase, but
this enzyme is inactive in most somatic cells. While telomere-related
signaling is considered a main barrier to malignant transformation, it
has become apparent that telomere dysfunction can fuel cancer
development through the induction of genome instability [5]. In
addition, accumulating DNA damage due to both endogenous and
exogenous sources has been proposed to be the origin of aging and
cancer. Stem cells are no exception with regard to DNA damage, albeit
possibly at a slower rate [6]. An important endogenous source of
damage is thought to be reactive oxygen species (ROS), which are a
normal consequence of metabolism. ROS can react with diverse
components of the cell, including lipids, proteins and DNA. Such
reactions might yield difﬁcult-to-degrade products and give rise to a
wide range of DNA lesions [7]. However, if and how aging of adult
stem cells is related to this is currently controversial and unclear [8].
For example, while the abundance and ability of hematopoietic stem
cells (HSCs) to form colonies does not seem to become impaired with
aging, skewing toward certain lineages is observed, pointing to cell-
intrinsic aging of these stem cells. On the other hand, the ability of
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on the age of the niche [8]. Aging is also accompanied by increased
accumulation of macromolecular and organelle damage and impair-
ment of autophagic processes that normally counteract this hasten
aging. Age-related impairment of lysosomal function, possibly as the
result of increased ROS levels within lysosomes and the accumulation
of lipofuscin, seems to be a main cause of reduced cellular turnover
[3].
It is appreciated nowadays that the function of many genes
inﬂuences aging. Here, we will discuss involvement of the insulin
pathway and its genes, which have set the paradigm for much of our
current understanding of aging.
2. Establishment of the PKB/FOXO switch
Ample evidence suggests that insulin and insulin-like growth
factor (IGF)-1 signaling (IIS) is important in determining life-span in
various organisms, including mammals. Initially, the life-extending
effects of dampening IIS were observed in the worm Caenorhabditis
elegans. Worms that harbor mutations in the DAF-2 gene live twice as
long compared to wild type worms [9]. DAF-2 encodes an orthologue
of the mammalian insulin and IGF-1 receptors and at that time
biochemical studies already provided possible mechanisms of signal
propagation, which could be involved in mediating DAF-2 inﬂuence
on lifespan. Binding of insulin to the insulin receptor (IR) results in
activation of the intrinsic tyrosine kinase activity of the IR and
consequent autophosphorylation and phosphorylation of cytoplasmic
substrate(s) on tyrosine residues [10]. Members of the insulin receptor
substrate-family (IRS-1/2/3/4) are the predominant IR substrate and
IRS-1 tyrosine phosphorylation provides access toward two major
downstream signaling cascades: the phosphoinositide-3 kinase (PI3K)
pathway and the Ras pathway [11]. SH2 domain-mediated binding of
the p85 regulatory subunit activates the catalytic p110 subunit of PI3K,
resulting in increased level of 3′ phosphorylated phosphoinositides
(PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3,5)P2 hereafter referred to
as PI3P lipids). Indeed, DAF-2 effects on lifespan were shown to involve
AGE-2 (the PI3K orthologue) and importantly also the transcription
factor DAF-16 [12,13].
Members of the Forkhead box-O class of transcription factors
(FOXO1, 3, 4 and 6 hereafter collectively referred to as FOXOs), are the
mammalian orthologues of DAF-16. By means of biochemistry the
signaling gap between PI3K and FOXOs has been closed. PI3P lipids
provide docking sites for proteins containing PI3P binding domains,
such as the pleckstrin homology (PH) domain. Importantly PI3P
increase results in activation PKB which harbors, next to the kinase
domain, a PH domain (reviewed in [14]). PKB activation is complex
and besides membrane recruitment requires phosphorylation at
Thr308 by Phosphoinositide-Dependent Protein Kinase1 (PDPK1),
another PH domain containing kinase. Full activation of PKB also
requires phoshorylation at the C-terminal Ser473 residue and several
kinases have been proposed to mediate Ser473 phosphorylation,
including PKB itself. At present genetic evidence suggest that depending
the context either DNA-PK and/or the mammalian target of rapamycin
(mTOR) complex 2 (mTORC2) mediate Ser473 phosphorylation
(reviewed in [14]).
The notion that PKB mediates PI3K signaling prompted the
possibility that FOXOs are direct substrates of PKB. Indeed, DAF-16
and FOXOs are direct substrates of PKB and are phosphorylated by PKB
on three conserved residues. PKB-mediated phosphorylation of FOXOs
results in 14-3-3 binding, and this correlates with nuclear export,
cytoplasmic retention, and inhibition of transcriptional activity of FOXO
(reviewed in [15]). The precise involvement of 14-3-3 in these
processes is still unclear, but PKB phosphorylation and 14-3-3 binding
occur in the nucleus and 14-3-3 binding reduces the afﬁnity of FOXOs
for DNA, and shields the nuclear localization signal (NLS), thereby
affecting nuclear import (reviewed in [15]).Besides PKB, PDPK1 can also activate other kinases of the AGC
family of kinases including the PKB related serum and glucocorticoid
inducible kinase (SGK) [16]. SGK can phosphorylate the same residues
as PKB on FOXOs albeit with differential efﬁciency. In agreement, SGK
is similarly implicated in C. elegans lifespan extension [17].
In addition to PKB and SGK, a number of other kinases have been
shown to phosphorylate FOXOs and to contribute to FOXO inactiva-
tion (reviewed in e.g. [15]). However, ROS activated signaling
involving c-Jun N-terminal Kinase (JNK) leads to nuclear localization
and activation of FOXOs, even in the context of active PKB (reviewed
in [18]). Activated JNK phosphorylates FOXO4 on a number of sites
and this coincides with MDM2-dependent mono-ubiquination,
nuclear localization and activation of FOXO4 transcriptional activity
[19]. Such JNK-mediated activation of DAF-16/dFOXO has also been
reported in C. elegans and Drosophila [20,21]. However, whether
JNK-dependent activation of FOXO4 applies to the other mammalian
FOXO family members remains to be established. Interestingly, JNK
opposing PKB signaling with respect to FOXO regulation (Fig. 1)
appears illustrative for a much broader network of antagonistic PKB/
JNK interactions [22].3. PKB peculiarities
The mammalian PKB/AKT family consists of three isoforms (PKBα/
AKT1 PKBβ/AKT2 and PKBγ/AKT3). PKBβ is the predominant isoform
in insulin sensitive tissues and cells. In agreement PKBβ−/−, but not
PKBα−/−mice display defective insulin-stimulated glucose uptake in
muscle and adipocytes. In adipocytes cultured from PKBβ−/− mice
this defect is relieved upon ectopic expression of PKBβ but not PKBα.
Thus PKBβ appears to be the main mediator of insulin-induced
glucose uptake [23–25]. The inducible glucose transporter GLUT-4 is
mainly responsible for the actual uptake of glucose after insulin
increase. Numerous components regulating GLUT-4 dynamics have
been identiﬁed and several of these are directly phosphorylated and
regulated by PKB [26].
In addition to regulation of glucose uptake insulin also regulates
storage of glucose into glycogen. Glycogen levels are controlled through
synthesis catalyzed by glycogen synthase (GS) and lysis by glycogen
phosphorylase. GS activity is repressed through phosphorylation by
glycogen synthasekinase-3 (GSK3).Duringbasal conditionGSK3activity
is high, but insulin-induced PKB activation results in PKB-mediated
phosphorylation of GSK3 on its regulatory sites Ser21 and Ser9
(numbering GSK3α and GSK3β respectively). This results in inhibition
of GSK3 activity and therefore increased GS activity [27].
Initially, it was shown that insulin through PKB could regulate
PI3K-dependent p70 S6kinase activity [28]. However, this remained
controversial until a series of genetic and biochemical studies outlined
the pathway in detail. In brief, it was shown that PKB regulates the
tuberous sclerosis 2 gene product (TSC2) by direct phosphorylation
[29]. TSC2 functions in complex with TSC1 and the TSC1/2 complex
has GTPase activating protein (GAP) activity. The small GTPase
regulated by the TSC1/2 complex was identiﬁed as Rheb, identiﬁed
previously as a component of the mTOR pathway by genetics in
Drosophila. PKB phosphorylation inhibits GAP activity of the TSC1/2
complex and therefore a model was put forward in which PKB,
through TSC1/2 and Rheb, regulates mTOR activity and hence p70
S6kinase. p70 S6kinase phosphorylates the 40S ribosomal subunit
thereby affecting protein translation, but through the mTOR and the
PI3K pathway PKB regulates many other players involved in protein
synthesis including eIF4GI, eIF4B, 4E-BP1 and 4E-BP2 [30]. This results
in a complex regulatory network the details of which are still not fully
understood. However the importance of this regulation is emphasized
by the observation that deregulated expression of these components
can cause (overexpression of eIF4E or eIF4G) or inhibit (overexpression
of 4E-BP-1 or 4E-BP-2) malignant cell transformation [31,32].
FOXOPKB JNK ROSINSULIN
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Fig. 1. The PKB/FOXO switch. FOXO transcription factors are predominantly controlled by two signaling pathways. First, the insulin pathway acting through PI3K and PKB-mediated
phosphorylation of FOXO, resulting in cytoplasmic retention and inhibition of FOXO transcriptional activity Second, a pathway activated by cellular stress acting through increased
ROS and JNK-mediated phosphorylation of FOXO resulting in increased nuclear localization and activation of transcriptional activity. The opposing forces of PKB versus JNK signaling
will determine whether FOXO will direct a transcriptional response regulating entry into quiescence or senescence. p27Kip1 and p21Cip1/WAF1 are provided as example of genes
regulated by FOXO tomediate quiescence or senescence onset respectively. However, other FOXO regulated genes are in addition involved in imposing these cell fates (for discussion
see text). Abbreviations. protein kinase B (PKB); c-Jun N-terminal Kinase (JNK); Reactive Oxygen Species (ROS); Forkhead Box O (FOXO).
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input toward mTOR. Nutrient sensing by cells is not fully understood
but lack or surplus of nutrients may change the AMP/ATP balance
within cells. Increased AMP/ATP ratio results in the activation of the
AMP-dependent kinase (AMPK) and its upstream activator LKB1.
AMPK can directly phosphorylate twomTOR regulators i.e. raptor and
TSC1 and thereby regulates the mTOR pathway. Besides regulated by
multiple inputs, mTOR also regulates outputs other than protein
synthesis, including regulation of autophagy, fat metabolism, and cell
cycle [33,34].
Whereas PKBβ is the isoform predominantly involved in regulat-
ing glucose homeostasis, PKBα appears to mainly regulate prolifer-
ation. Aberrant activation of PKB in human cancer is largely due to loss
of PTEN, but hyperactivity of PKB due to overexpression and gene
mutation (E17K) have also been described [35]. PTEN heterozygous
mice (PTEN−/+) develop a wide range of tumors with high incidence
and at early age. Strikingly, crossing these mice with mice nullizygous
for PKBαmarkedly decreases tumor development in some but not all
tissues [36,37]. Thus PKB is involved in a variety of processes and we
will further focus on the co-involvement of PKB and FOXO in some of
these processes.
4. The PKB/FOXO sandwich
Given its involvement in a large variety of cellular processes PKB
has been shown to phosphorylate directly a large and diverse array of
substrate proteins. Although the extent and rigor bywhich the various
PKB substrates are deﬁned differs signiﬁcantly, and probably not all
will turn out genuine PKB substrates (reviewed in [38]) it is
noteworthy that a number of these substrates as well as the events
controlled hereby are also regulated by FOXO. In keeping with PKBacting as a negative regulator of FOXO the effect of FOXO on these
substrates opposes that of PKB (Fig. 2).
Firstly, FOXOs activate transcription of the cell cycle inhibitor p27Kip1
and p21Cip1/WAF1while they repress transcription of cyclin D1 and cyclin
D2 (reviewed in [15]). PKB phosphorylates p27Kip1 on Thr157 [39–41],
resulting in 14-3-3 binding and cytosolic retention [42]. Interestingly,
p27Kip1 localized in the cytosol is ineffective in blocking cell-cycle
progression, but promotes cell migration and movement [43]. It should
be noted however, that the PKB phosphorylation site Thr157 is not
conserved in rodent versions of p27Kip1. However, it has been suggested
that in these species other sites of PKB phosphorylation may substitute
for Thr157 phosphorylation, as otherwise similar to non-rodent cells
and human p27Kip1, relocalization of p27Kip1 following PI3K/PKB
activation in rodent cells is observed [44]. PKB has also been found to
phosphorylate the cyclin-dependent kinase inhibitor p21Cip1/WAF1 on
Thr145, and, like p27Kip1, this phosphorylation leads to p21Cip1/WAF1
cytosolic localization [45]. Interestingly, it has been suggested that
PKBα, but not PKBβ, phosphorylates and inhibits p21Cip1/WAF1, whereas
PKBβ appears to bind and stabilize p21Cip1/WAF1, thereby blocking
cell-cycle progression [46]. What these ﬁndings indicate in terms of the
differential involvement of PKBα and PKBβ in the proliferative versus
metabolic response to insulin is unclear. In addition, PKB can indirectly
inhibit p21Cip1/WAF1 expression through phosphorylation and activation
of MDM2 and subsequent down-regulation of p53-mediated transcrip-
tion of p21Cip1/WAF1 [47,48]. It is unknown whether this regulation of
MDM2 involves a preferential PKB isozyme.
Secondly, active PKB mediates GSK3 phosphorylation and inhibition
ofGSK3activity [14]. GSK3-mediatedphosphorylationof cyclinD, cyclinE
and c-MYC targets thempolyubiquitination and subsequent proteasomal
degradation [49–51]. Consequently, PKB-mediated phosphorylation and
inhibition of GSK3 activity will increase cyclin D, cyclin E and c-MYC
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mechanism that is not fully understood [52,53]. Furthermore, c-MYC
opposes FOXO function (see further for discussion).
Lastly, besides acting in an antagonistic manner on critical cell
cycle progression regulators, FOXOs also act to antagonize the
activation of mTORC1 by PKB. Sestrins were initially discovered as
downstream transcriptional targets of p53 and potentially involved in
antioxidant defenses. Sestrins display cysteine sulﬁnyl reductase
activity in vitro and are therefore able to regenerate overoxidized i.e.
containing Cys-SO2H, peroxiredoxins [54]. However, sestrins display
no sequence similarity to sulﬁredoxin (Srx) the other known cysteine
sulﬁnyl reductase, and sestrin reductase activity could not be
conﬁrmed in another independent study [55]. Thus the mechanism
by which sestrins contribute to increased anti-oxidant capacity
remains unclear. Sestrin expression is also regulated by FOXOs [56]
and in Drosophila chronic mTOR activation results in increased sestrin
expression through increased ROS and JNK-mediated dFOXO activa-
tion [57]. How sestrins inhibit mTORC1 is subject to some debate with
regard to the requirements for the TSC1/2 complex (compare [54,57]
and [58]), but activation of AMPK is always observed [54,57,58]. In
addition, Drosphila FOXO has been shown to regulate the expression
of 4E-BP, reducing downstream signaling by mTORC1 [59,60]. Thus
FOXOs, indirectly via sestrin regulation counteracts again PKB in this
case in regulating mTOR.
5. Supersizing the sandwich: feedback signaling directly from
FOXO to PKB
Whereas FOXOs appear to generally inhibit signaling downstream
of PKB, a number of upstream regulators of PKB are positively
regulated by FOXO-mediated transcription. While IRS-2 [61], PI3K
(p110α) [62] and the insulin receptor [60,63] seem to be direct
transcriptional targets of FOXOs, increased Rictor expression is
independent of DNA binding [58]. However, and importantly, mere
increased expression of either of these components will not be
sufﬁcient to activate PKB and activation still requires an input signal,p21cip1mdm2
2mdm p21cip1p53
FOXO
FOXO
p53?
Fig. 2. The PKB/FOXO sandwich. In addition to the direct control of FOXO by PKB, a number o
FOXO controls transcription of several PKB substrates especially genes involved in regulating
in regulating p53, but also FOXO ubiquitination and is transcriptionally controlled by p53, bu
increase its stability and impair p53 dependent p21Cip1/WAF1 transcription and possibly also i
this see [19]). Abbreviations: murine double minute 2 (MDM2), others see Fig. 1.such as insulin. In this respect it is of interest that in Drosophila
activation of JNK results in the downregulation of DILP2 expression
(insulin resembling peptide) in a dFOXO-dependent manner [64].
The general picture that emerges from these observations – e.g.
FOXOs inhibiting downstream signaling of PKBwhile at the same time
enhancing expression of upstream regulators – is a model that favors
fast switching (Fig. 3). From an evolutionary viewpoint, such rapid
responses could have signiﬁcant advantages. For example during
development of C. elegans larvae DAF-16 is activated due to stresses
such as food shortage. DAF-16 activation causes a developmental
arrest called Dauer and exit of Dauer occurs when stress is alleviated
e.g. upon increased food availability. To be able to take advantage of
the newly available nutrients, individuals should respond fast. Given
regular occurrence of nutrient shortage, a shorter response speed
would provide individuals with an advantage over those that respond
slower. By narrowing the signaling system during periods of stress to
the regulation of a single switch (PKB/FOXO) the organism enhances
its speed of response when stress is alleviated. In addition, the
reciprocal relationship between PKB and FOXOs ensures robust,
binary switching. Apparently this type of stress response has been
conserved in mammalian cells where FOXOs also maintain the
possibility of rapid and strong PKB activation by upregulating
upstream activators, whilst inhibiting downstream PKB signaling.
When stress is relieved and signals driving PKB are again present,
FOXOwill be robustly switched off, as no feedback or interference will
come from other downstream PKB signaling. Because all other PKB
signaling is temporarily shut down by FOXO this will also allow for a
rapid reactivation response of these other PKB regulated events.
Interestingly, the robust switching ensured by FOXOs and
performed by DAF-16 in a whole organism, may also operate in a
cell-autonomous manner and it may thus be concluded that cells
compete with each other for rapid PKB activation and loss of FOXO
function, a model of cell competition that will be interesting to
investigate. In addition this would predict/rationalize how cancer
cells that have lost FOXO function due to PI3K/PKB activation compete
with normal cells during for example nutrient stress.PKB
GSK3
cyclinD p27kip1
1pik72pcyclinD FOXOFOXO
f proteins are controlled separately by PKB and FOXO giving rise to antagonistic control.
cell cycle progression (p27Kip1, p21Cip1/WAF1, cyclin D1 and cyclin D2). MDM2 is involved
t possibly also by FOXO (BB, unpublished observations). PKB phosphorylates Mdm2 to
nduce MDM2-mediated polyubiquitination and degradation of FOXO (for discussion on
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linked to at least two major cell regulatory events namely cell cycle
regulation and mTOR-dependent signaling. This implies a role for the
PKB/FOXO switch in two mechanisms of tumor suppression that are
also directly linked to aging, namely autophagy and senescence which
will be discussed brieﬂy.
6. Mechanisms of tumor suppression affecting aging: autophagy
Aging is accompanied by increased accumulation ofmacromolecular
and organelle damage and impairment of autophagic processes that
normally counteract these aspects of aging. Age-related impairment of
lysosomal function, possibly as the result of increased ROS levels within
lysosomes and the accumulation of lipofuscin, seems to be a cause of
reduced cellular turnover [3].
The lysosomal network is themajor system that degrades long-lived
proteins and larger structures, resulting in the release of raw building
blocks to the cell [3]. Autophagy – to eat oneself – is a highly conserved
pathway that is responsible for bulk degradation of cytoplasmic
components through the lysosomal pathway. Among the several types
of autophagy that are distinguished, macroautophagy and chaperone-
mediated autophagy (CMA) are the best studied. Macroautophagy –
whichweandothers refer towhen speaking about autophagy– involves
engulving part of the cytoplasm inside double-membrane vesicles
termed autophagosomes. These then fuse with lysosomes, which aids
the degradation of the cargo [3]. The family of ATG-genes was ﬁrst
discovered in yeast tobe essential formacroautophagy.At least 30genes
are nowadays recognized to be actively involved in this process and
another 50 are implicated in the regulation of the process [65].
Macroautophagy is regulated downstream of mTORC1 by the ULK1-
complex, that contains ULK1, mAtg13 and FIP200 [66]. ULK1 and
mAtg13 both bind directly to mTORC1 and ULK1 does so through
interaction with the mTORC1-speciﬁc subunit Raptor. Both are thought
to be phosphorylated by mTORC1, reducing their binding to one-
another and the kinase activity of ULK1. Formation of the complex is a
critical step in proper localization of the ULK1-complex, and activation
of autophagy. In yeast, Atg17 is the most upstream protein responsible
for proper localization and initiation of autophagy and FIP200 is thought
to be the functional homologue of Atg17 [65]. Autophagosome
maturation and lysosome fusion requires a number of additional
steps, which have been extensively described (see for example [3]).
Interestingly, a number of feedback loops seem to regulate these
processes, in particular in autophagy-initiation involving mTORC1 and
the ULK1-complex. For example, it has been shown that ULK1 itself can
phosphorylate mAtg13, which is predicted to cause inactivation of the
complex, although not all data are consistent with such amodel [65]. In
addition, in Drosophila and mammals, ULK1 ablation or knockdown
results in mTORC1 activation, pointing to a negative feedback [66].
As mentioned, autophagy has been implicated in both aging and
disease [3,67]. The most frequently reported characteristics of cells
defective in autophagy are the progressive accumulation of protein
aggregates andmitochondriawith aberrantmorphology.Whilemice that
lack Atg5, Atg7 or Atg3 fail to survive the neonatal starvation period [67],
tissue speciﬁc knockouts and pharmacological intervention have shed
light on the consequences of loss of autophagy. For example, loss of
autophagy in the nervous system results in the formation of inclusion
bodies and neural degeneration with age [68,69], while mice exposed to
theClass III PI3K-inhibitor3-methyladenineshowexcessiveaccumulationFig. 3. The PKB/FOXO super-size sandwich. Besides antagonistic interactions between FOXO
involved in mediating PKB activity upon exposure of cells to extra-cellular ligands such as i
ROS-dependent signaling, the PKB/FOXO switch is set to active FOXO (indicated by enlarged
control of ROS. In addition upstream PKB signaling is set to optimal response in case conditio
(indicated by enlarged PKB icon), followed by rapid shutdown of FOXO (indicated by re
metabolism and ROS control. Abbreviations: Insulin Receptor (IR), Insulin Receptor Subst
Protein Kinase1 (PDPK1), mammalian Target Of Rapamycin Complex 1 (mTORC1), mammaof triglycerides and lipid drops, especially in the liver [70]. Furthermore,
clearance of mitochondria from reticulocytes is an essential step in their
development and as such impairment of this process results in anemia
[71]. Autophagy probably has a dual role in cancer development, being
suggested to both prevent and facilitate cancer development. On the one
hand, autophagy is thought to be essential for tumor cell survival,
providing a mechanism to sustain viability under growth limiting
conditions that are thought to be imposed on cancer cells frequently.
On the other hand however, cancer development can be enhanced in
settings of sustained inﬂammatory response, for example due to defective
clearance of apoptotic cells. Thus, choosing between inhibiting or
activating autophagy in cancer therapy is not a straightforward decision
[67]. Given the above described, it is not surprising that autophagy is
linked to aging and age-related deterioration of tissues [3]. In model
organisms, autophagy has been shown to be important in aging and
life-span. Interestingly, both Dauer-formation and life-span extension
observed in C. elegans mutant for DAF-2 are dependent on the Beclin 1
homologue of C. elegans bec-1 [72]. Furthermore, autophagy itself seems
to be subject to aging. One of the hallmarks for this is the age-dependent
accumulation of lipofuscin in lysosomes. The exact origin of lipofuscin is
unknown, but it is thought to be constituted of oxidized, undegradable
molecules that may contain iron, as deduced from their yellow/brown
coloring. Lipofuscin accumulation is thought to contribute to declining
autophagy, possibly through reducing the ability of autophagosomes to
fuse with lysosomes [3].
Decreased/loss-of-autophagy does not affect all tissues to the same
extent, which can be explained by the fact that some tissues contain
more long-lived or stressed cells than others [67]. For example,
skeletal muscle are believed to have low cell turnover [8] and the
maintenance of muscle mass is dependent on functional autophagy
[73,74]. PI3K-PKB and FOXO-signaling has been shown to be critically
important for muscle hypertrophy and atrophy respectively [75–77].
Muscle atrophy is regulated by both ubiquitin-ligase dependent
degradation as well as autophagy [78]. FOXOs ability to cause atrophy
was initially attributed to its ability to regulate the expression of two
muscle-speciﬁc E3-ubiquitin ligases, namely Atrogin-1/MAFbx and
MuRF1 [75,79]. More recently, FOXOs were also shown to directly
regulate autophagy-related genes in muscles, and other cell types, both
in vitro and in vivo [76,78,80]. Autophagy is negatively regulated by
mTOR-signaling, which is in turn positively regulated by PI3K-PKB. In
agreement with the requirements of autophagy in life-span extension
of DAF-2 worms, FOXOs have been shown to regulate autophagy both
directly and indirectly. Firstly, FOXO3 was shown to regulate a number
of genes that are directly involved in autophagy, such as Gabarapl1
(Atg8), LC3b and Atg12L [76]. Secondly, FOXOs were described to
regulate one of the family members of the sestrins, sestrin 3 [56–58].
Sestrins can inactivate mTORC1 in an AMPK-dependent manner [54]
and have been implicated in ROS scavenging [56] (see also above). In
Drosophila, constitutive activation of the mTOR-pathway causes
upregulation of dSESN, which is dependent on ROS-activated JNK
and dFOXO. In the absence of dSESN, these ﬂies display lipid
accumulation, decreased cardiac function, skeletal muscle degenera-
tion and mitochondrial dysfunction [57]. These hallmarks of aging are
also observed in ﬂies that lack one of the constituents of autophagy
(Atg1) [57], although this formally does not show that dFOXO exerts its
protective function through autophagy. Another study showing the
importance of FOXOs in age-related protein homeostasis – called
proteostasis by the authors – implicates another dFOXO target, 4E-BP,and PKB, FOXO activity also increases expression of a number of PKB regulators that are
nsulin. Under adverse conditions such as environmental stress due, to amongst others
FOXO icon) and cells cease to proliferate, switch to FOXO-dependent metabolism and
ns change to favorable. In case of favorable conditions insulin will drive PKB activation
duced FOXO icon) and loss of proliferation inhibition and accompanying changes in
rate-1 (IRS1), phosphatase and tensin homolog (PTEN), Phosphoinositide-Dependent
lian Target Of Rapamycin Complex 2 (mTORC2).
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4E-BP indeed are in part through upregulation of genes involved in
autophagy, as reduction of Atg7 partly attenuates the beneﬁcial effects
of dFOXO/constitutive active 4E-BP expression [81]. Although the
above described data seem to be conﬂicting – FOXOs causing muscle
atrophy through autophagy, while loss of autophagy also results in
atrophy – dynamic regulation of muscle size in response to exercise
andmaintenance of muscle-cell integrity are clearly different aspects of
muscle-biology.
7. Mechanisms of tumor suppression affecting aging: senescence
When primary normal diploid cells are taken into culture these
cells arrest after about 50 cell divisions in vitro and lose the ability to
divide. This arrest is termed senescence and initially characterized as
being permanent i.e. cells are no longer able to re-enter the cell cycle.
This, trait distinguishes senescence from quiescence, the latter being
characterized as reversible. However, studies have shown that
p53-induced senescence is potentially reversible [82]. Consequently, it
has proven difﬁcult to establish a conclusive cellular marker of the
senescent condition and hence difﬁcult to establish whether senescent
cells are present in living organisms or whether they are a cell culture
artifact. Nevertheless, cells showing classical markers of senescence e.g.
SA-β-galactosidase activity, are observed in vivo and currently the
presence of senescent cells in vivo is accepted. Because senescence is
under most conditions a permanent withdrawal of the cell cycle, it is
considered a potential mechanism of tumor suppression. Indeed,
oncogene expression was found to induce premature senescence in
primary cells and senescence bypass is therefore a requirement of
tumorigenesis.
Senescence is considered a stress response and various types of
cellular stress, e.g. DNA damage and increased ROS can cause
senescence onset. Human primary cells lack telomerase expression
and progressive telomere shortening due to replication is thought to
result in a chronic DNA damage response and induces senescence
termed ‘replicative senescence’. Mouse primary cells when taken into
culture at ambient oxygen suffer from hyperoxia and consequent
oxidative stress triggers senescence onset, as reducing oxygen levels
to apparent normoxia (approximately 3% O2) greatly enhances the
number of cell doublings before senescence onset [83]. Compared to
human primary cells, mouse primary cells express high telomerase
activity and this may reveal a relative large contribution of ROS to
senescence onset in mouse cells. However, also for human primary
cells cellular ROS is important in senescence onset [84].
Because of the involvement of FOXOs in regulating cellular ROS, a
role for FOXOs in ROS-mediated senescence can be invoked. In
agreement with the role of FOXOs in ROS homeostasis, PKBα/β−/−
MEFs (active FOXOs) are relatively resistant to signaling induced by
ROS. Conversely, cells expressing active PKB (inactive FOXOs) are
relatively sensitive to ROS signaling, including senescence induction
[56]. In agreement with ROS contributing to oncogene-induced
senescence, RAS-induced senescence was impaired in PKBα/β−/−
MEFs [56]. However, it has also been suggested that a RAS-dependent
negative feedback loop that represses PI3K-PKB/AKT activity [85] is
responsible for induction of RAS-induced senescence.We showed that
ectopic expression of FOXO4 and ROS-mediated activation of FOXO4
in BRAFV600E melanoma cells induces senescence [86]. Moreover,
recent genetic evidence has shown that loss of PTEN inactivation
strongly cooperates with BRAFV600E to drive melanoma progression
[87]. This would suggest that FOXO inactivation resulting from loss of
PTEN at least in melanoma development can mediate a senescence
bypass.
Can these contradictory results regarding the involvement of
FOXOs in senescence induction in the aforementioned studies be
reconciled? Most certainly, oncogene induced senescence is only a
partly understood phenomenon. At present several pathways bywhich oncogene expression induces senescence have been described
and it is unclear whether these are general or oncogene speciﬁc. For
example, whereas RAS proteins are upstream regulator of RAF kinases,
oncogenic HRASG12V expression in primary melanocytes induces
senescence through the ER-associated unfolded protein response,
whereas oncogenic (B)RAF does not [88]. Furthermore, these
differences between RAS and RAF are also reﬂected in mice models
in which BRAFV600E can induce melanoma and hence a senescence
bypass [89], whereas HRASG12V and NRASQ61K can induce melanoma
only if combined with loss of tumor suppressors such as p16Ink4a or
p19Arf [90,91]. Besides oncogene-speciﬁc differences in senescence
induction, differences between cell types may also play a role. At least
in cell culture systems, ﬁbroblast senescence differs from melanocyte
senescence (discussed in [92]). Summarizing, p16Ink4a-deﬁcient
mouse or human ﬁbroblasts senesce normally, but mouse or human
melanocytes deﬁcient for p16Ink4a show an impaired senescence
response and extended life-span (number of passages before they
become senescent) [92]. Although clearly oncogene and cell type
speciﬁc mechanisms of senescence induction are relevant and may
explain differential involvement of FOXO in senescence, it remains
that senescence in general, including melanocyte senescence [93]
frequently correlates with elevated levels of ROS and oncogene
induced senescence can also be bypassed by ROS scavenging
compounds such as N-Acetyl Cysteine (NAC) [94,95]. How increased
ROS exactly contributes to senescence is unclear at present but
activation of p53 and/or induction of DNA damage are observed after
increased cellular ROS and in agreement both can induce senescence.
ROS-regulation of FOXO may also provide an explanation for the
differential involvement of FOXOs in senescence. Decreased growth
factor signaling results in activation of FOXO through loss of inhibition
by PKB, whereas increased cellular ROS activates FOXOs through a
distinct mechanism involving JNK. These separate modes of FOXO
activation do not necessarily result in the same activation of
downstream signaling. Indeed, we observe a ROS-induced FOXO4-
dependent increase in p21Cip1/WAF1 expression, whereas growth
factor deprivation-induced FOXO4 activity resulted in induction of
p27Kip1 expression. The ﬁrst is associated with senescence induction,
whereas the latter is involved in the induction of quiescence [96].
Thus distinction needs to be made between these two modes of FOXO
activation. In addition, the sensitivity of various signaling molecules
such as FOXO and PKB toward ROS enables differential regulation. For
example, when comparing FOXO and PKB, FOXO regulation by ROS, as
induced by hydrogen peroxide treatment, occurs already at low
concentration (10–25 μM H2O2) whereas PKB activation requires a
relative high concentration (200–500 μM H2O2) ([97], unpublished
results). Thus, FOXOswill responddifferent to changes inROS levels and
in general be activated by relative small changes in cellular ROS levels
and inactivated at high ROS levels. Thus sensitization of cell or biological
systemswill occur by depletion of PKB or FOXOandwill shift systems to
increased or decreased sensitivity toward changes in the levels of
cellular ROS. Although not investigated in detail, such differences will
probably occur inmost studies employing geneticallymodiﬁedmice e.g.
[98]. Finally, thedifferent and context-dependent involvementof FOXOs
in senescence as outlined above is further indicated by more general
observations. Senescence is considered amechanism of tumor suppres-
sion and FOXOs are genuine tumor suppressors [99], hence senescence
induction would be a means to achieve this function. However, and in
contrast, cellular senescence contributes to aging [100,101] and active
FOXOs increase lifespan so could therefore be expected to reduce
senescence. Importantly these considerations may be taken to suggest
that the different and context-dependent functions of FOXOs to regulate
senescence and tumor suppression provide a basis for the idea that
FOXOs mediate the trade-off between tumor suppression and lifespan.
Interestingly, c-MYC overexpression is reported to suppress
BRAFV600E-induced senescence in melanoma cells [102] and this is
independent of p16Ink4a and p53. Asmentioned previously, FOXOs can
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independent of p16Ink4a [86]. Furthermore, c-MYC suppression of
RAS-induced senescence requires CDK2 phosphorylation of c-MYC
[103]. CDK2 also phosphorylates FOXO1 resulting in cytoplasmic
retention of FOXO and hence inhibition of its transcriptional activity
[104]. These observations suggest that c-MYC requires FOXO inhi-
bition to prevent senescence onset in melanoma and are illustrative
for the reciprocal relation between FOXOs and c-MYC as discussed
below.
8. FOXOs clash with c-MYC
The classical experiment [105] demonstrating the necessity for
cooperation between oncogenes in driving tumorigenic transforma-
tion of primary cells, employed a combination of mutant HRAS and
overexpression of c-MYC. Initially, we observed a block in cell cycle
progression of HRAS transformed cells following ectopic expression of
FOXO4 and this suggested FOXOs to act as tumor suppressors, at least
in the context of oncogenic RAS driven tumorigenesis [106]. To drive
oncogenic transformation RAS employs several downstream signaling
pathways most importantly PI3K, Ral and MAPK signaling (reviewed
in [107]). Thus, oncogenic RAS expression results in increased PKB
activation and in agreement with RAS and c-MYC as cooperating
oncogenes, constitutive PKB activity synergizes with c-MYC in the
Eμ-MYC mouse lymphoma model [108]. Combining these observa-
tions suggested that loss of FOXO activity could possibly also
cooperate with c-MYC to drive cellular transformation. Indeed, ex-
pression of a dominant-negative form of FOXO enables c-MYC to
induce foci formation of primary cells in the absence of oncogenic RAS
[109]. The mechanism underlying the observed cooperation between
c-MYC and loss of FOXO appears to be part of what we like to refer to
as a general “clash between FOXO and c-MYC” resulting in a reciprocal
inhibition of transcriptional activity between FOXOs and c-MYC
(Fig. 4). Repression of c-MYC transcriptional activity occurs through
FOXO-dependent induction of expression of several members of
the Mad/Mxd family of transcriptional repressors, most the notably
Mxi1-SRα isoform [110]. Importantly, this results in a partial inhi-
bition of the c-MYC transcriptional program as many but not all
c-MYC target genes are repressed by FOXOs. Nevertheless, FOXO
repression of c-MYC results in reduced cell cycle entry following
c-MYC activation [111]. Importantly, repression of c-MYC in return
contributes to the cell cycle arrest imposed by active FOXO as
silencing of Mxi1 alleviates this. Furthermore, FOXOs impose a cell
cycle arrest by induction of cell cycle inhibitors such as p27Kip1 and
p21Cip1/WAF1 and repression of cyclin D1 and cyclin D2. Early studies
already showed that c-MYC represses FOXO-induced p27Kip1 [112].
How c-MYC represses p27Kip1 expression is not fully understood but
likely involves Miz-1 [113]. c-MYC also represses p21Cip1/WAF1
expression and induces cyclin D1, cyclin D2 and cyclin D3 expression
[114,115]. However, as yet, only direct binding of c-MYC to the
promoter of cyclin D2 has been reported [116]. Importantly, c-MYC
and its repression of p21Cip1/WAF1, and cyclin D1 are suggested to be
important mediators of canonical Wnt signaling downstream of TCF/
β-catenin activation [117]. Interestingly, FOXOs also bind to β-catenin
and this partakes in FOXO-mediated repression of TCF signaling
(reviewed in [118]). Although this suggests the FOXO/c-MYC antago-
nism to be important in tuning Wnt and PI3K/PKB signaling, it is
important to note that FOXOs only repress TCF/β-catenin under
conditions of increased ROS [119,120]. Also, we observed p21Cip1/WAF1,
rather than p27Kip1 the preferred FOXO target under increased ROS [86].
Thus, an interesting suggestion that can be derived from these studies is
that antagonistic regulation of p21Cip1/WAF1 by c-MYC and FOXO occurs
under increased ROS whereas during growth factor PI3K/PKB signaling
the clashoccurs throughp27Kip1 andcyclinDexpression.The importance
of this distinction between conditions of enhanced ROS versus growth
factor signaling in the antagonism between c-MYC and FOXOs may beillustrated further by the observation that loss of c-MYC impairs
RAS-driven tumorigenesis, but the subsequent loss of p21Cip1/WAF1
alleviates this [121]. c-MYC activity can induce both proliferation and
apoptosis, but normally these two responses cancel each other out.
Therefore, it is believed that for efﬁcient tumorigenesis drivenby c-MYC,
apoptosis-induction needs to be repressed relative to the proliferative
response. c-MYC activates the p19ARF-MDM2-p53 pathway to suppress
tumorigenesis by p53-dependent apoptosis [122] and in agreement
with the above spontaneous inactivation of the p19ARF-MDM2-p53
pathway occurs at high frequency in Eμ-MYC driven lymphomagenesis
[123]. Recently, it was shown that impairing FOXO activity by
expression of a dominant-negative form of FOXO alleviates the need
to loose p53 function in Eμ-MYC lymphomagenesis. This was attributed
to the ability of FOXOs to regulate p19ARF transcription, which was
impaired by expression of a dominant-negative FOXO. Thus under
normal circumstances, FOXOs counteract c-MYC induced proliferation
by regulating the p19ARF-MDM2-p53 pathway [111]. Although the
mechanism by which c-MYC would increase FOXO mediated p19ARF
transcription has not been elucidated, it is noteworthy that c-MYC is
reported to increase cellular ROS [95] and that increased ROS activates
FOXOs [18]. Dependence on ROS signaling would agree with the
observed importance of p21Cip1/WAF1 deregulation in tumorigenesis
following c-MYC activation [121] as, similar to p53, p21Cip1/WAF1 is
targeted by FOXOafter cellular stress [86]. Loss of p21Cip1/WAF1 enhances
p53-dependent apoptosis due to the loss of p53-dependent cell cycle
arrest [124] suggesting that in tumorigenesis, repression of p21Cip1/WAF1
by c-MYC also requires loss of FOXO/p53 dependent signaling as
otherwise increased proliferation will be canceled out by increased
apoptosis. Thus, besides inhibition of the apoptosis arm also loss of
repression on proliferation is important for c-MYC induced tumorigen-
esis. The possible importance of this feedback loop and the involvement
of FOXO repression in c-MYC induced tumorigenesis are further
illustrated by the observation that concomitant loss of p53 and PTEN
within the mouse central nervous system resulted in the onset of
malignant glioma resembling human glioblastoma characterized by
strong c-MYC activation. Thus, it may be concluded that loss of c-MYC-
induced control of FOXOdependent p19ARF transcription and hence p53
activation is insufﬁcient to induce malignant glioma, and that further
inhibition of FOXO function by PTEN deletion is required. Finally, a
recent study showed that inmicemodels FOXOs block progression from
benign polycystic kidneys to renal tumors via suppression of c-MYC
through upregulation of the c-MYC antagonists Mxi1-SRα andmiR-145
[125]. This provides further proof for the functional relevance of the
c-MYC/FOXO antagonism in tumorigenesis as well as an additional
perspective on the role of FOXOs as tumor suppressors.
9. Stem cells and the c-MYC and FOXO antagonism
Embryonic stem cells are rapidly cycling cells whereas adult stem
cells can be divided into a relative quiescent dormant adult stem cell
population and a population of stem cells that have exited quiescence
and become rapidly proliferating yet fully competent stem cells (for
discussion see [126]). Although this distinction may not fully apply to
adult stem cells of all tissues, a number of adult stem cells such as
those of the hematopoietic system have been shown to switch
between a quiescent and proliferative self-renewing state [127]. Loss
of FOXO in haematopoietic stem cells (HSC) results in uncontrolled
switching from quiescence to proliferation, increased proliferation
and (premature) exhaustion of the stem cell pool [128]. These
observations are in line with observations in PTEN−/− [129] and PKB
overexpressingmice [130], strongly suggesting the PKB/FOXO switch to
be important in determining stem cell fate and/or stem cell renewal.
Accordingly with the above described FOXO/c-MYC antagonism, c-MYC
deﬁciency in the haematopoietic system resulted in an increased
number of quiescent HSCs and conversely c-MYC activation resulted in
loss of HSCs [131]. However, it has also been suggested that c-MYC is
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Fig. 4. de c-MYC FOXO clash. Analysis of available literature indicates an extensive network of antagonistic c-myc FOXO interactions. First, FOXO and c-myc regulate shared target
genes in an opposing manner and this is illustrated by the p27Kip1 gene. Here, MIZ-1 binds to speciﬁc sequence elements present in the promoter of certain genes repressed by c-
MYC, including the p27Kip1 gene. MIZ-1 binding is required for c-MYC to repress p27Kip1 gene expression. In contrast, FOXO binds to the p27Kip1 promoter directly and activates
p27Kip1 gene transcription.Second, FOXOs regulate gene expression of a number of negative regulators of c-MYC, most importantly Mxi1-SRα. This results in a general attenuation of
c-MYC activity.Third, FOXOs can regulate p19ARF expression and as such participate in a c-MYC negative feedback loop to increase p53 activity and to repress c-MYC induced
apoptosis. Abbreviations: Alternative Reading Frame (ARF) of the CDKN2A gene. p19 indicates the molecular weight (in kD) of the gene product in humans. MAX-interacting protein
1 (Mxi1), SRα indicates an isoform with enhanced repressive potential. MYC-interacting Zn ﬁnger protein-1 (MIZ-1).
1934 D.E.A. Kloet, B.M.T. Burgering / Biochimica et Biophysica Acta 1813 (2011) 1926–1937important in the regulation of differentiation of HSCs (reviewed in
[132]).
Premature stem cell differentiation in FOXO deﬁcient mice has also
been reported for both neuronal stem cells [133,134] and follicle cells
[135]. These results further conﬁrm an important role of FOXOs in stem
cells,where theymaybe important to establish thequiescent state. This is
in line with our observation that in some cells ligand-independent
activation of FOXO results in a reversible cell cycle arrest indicated as
quiescence as itwas characterizedbyhallmarksof quiescence i.e. reduced
35S-methione incorporation, p130Rb2 activation and a consequent shift
in activity of the E2F family of transcription factors [136]. Interestingly,
others showed that one of the target genes of FOXO involved in ROS
scavenging –Manganese SuperOxideDismutase (MnSOD) [137] – is also
required for acquiring the quiescent fate [138]. Thus, quiescence appears
to depend on, as well as coincide with FOXO-induced changes in ROS
control. In agreement, stem cell depletion due to loss of FOXO correlates
with an increase in cellular ROS, at least in HSCs and neural stem cells
[128,133].
Duringaging, stemcell function is essential for replenishingdamaged
tissue with new cells and adult stem cell dysfunction is therefore
considered a major cause for loss of tissue homeostasis in aging
(reviewed in [6]) However, the mechanism underlying age-dependent
decline in stem cell function is still not understood. In general it appears
that the mechanisms that restrict cancer are also limiting stem cell
function, hence the strong functional similarities between cancer and
stem cells. Therefore, telomere shortening, DNA damage and increased
ROS may all contribute to gradually disabling stem cell function. As
discussed, the PKB/FOXO switch appears relevant to regulate the
reversible transition of stem cells between proliferation and quiescence.
However, proliferative capacity per se does not necessarily decline
during aging [6] suggesting that the switchmay function equally well at
old age. However, the setup of this switch is strongly linked to external
cues andsurprisingly several transplantationexperiments, inwhich cells
derived from young animals are transplanted to aged animals, have
shown signs of “rejuvenation” [139]. Apparently, external cues are
relevant to stem cell aging and hence may impinge on the PKB/FOXO
switch. In addition, as argued above regulation of FOXO by PKB differs
from regulation of FOXO by ROS, especially in the context of shifting
from quiescence to senescence. Thus, increased ROS and ROS-induced
damage accumulating during aging may force FOXOs to tilt towardsenescence rather than quiescence and thereby reduce stem cell ﬁtness,
without an apparent reduction of stem cell numbers. In agreementwith
an important role for senescence mechanisms in the functional decline
of stem cells are observations that important regulators of senescence
e.g. p16Ink4a and p21Cip1/WAF1 affect stem cell function. Expression of
p16Ink4a increases during aging and mice overexpressing p16Ink4a show
p16Ink4a not only to be a marker of aging, but also to contribute to
age-induced regenerative failure of tissues [140–143]. Likewise, p16Ink4a
deﬁciency partly rescued age-induced decline in stem cell function. In
micewith dysfunctional telomeres loss of p21Cip1/WAF1 partially extends
longevity of these mice and attenuates the proliferative defects,
importantly without increased tumorigenesis [144]. Thus, current
knowledge on extrinsic as well as intrinsic mechanisms of stem cell
dysfunction during aging suggests senescence as an important mech-
anism to limit stem cell function.
Stem cell dysfunction could also be a major contributor to cancer.
Cancer initiating cells, or cancer stem cells, are believed to represent the
resilient population of cancer cells that ‘regenerate’ tumors following
stress insults, including chemotherapy. At present the cancer initiating
cells are mostly studied based on their ability to cause tumor formation
in a recipient mice following transplantation. Interestingly, FOXO3a-
deﬁciency disables cancer-initiating cells in chronic myeloid leukemia
to cause tumor formation [145]. As FOXO deﬁciency also impairs the
ability of normal HSCs to repopulate the bonemarrow of recipient mice
in serial transplantation experiments, this indicates a similar defect to
underlie the role of FOXO both in normal as well as in cancer stem cells.
As argued the PKB/FOXO switch is primarily directed to regulate
transition between quiescence and proliferation. Following this line of
reasoning cancer initiating cells should express markers of quiescence.
Indeed, a subpopulation of melanoma cells is slow cycling and they can
maintain tumor growth, suggesting quiescence to be involved [146].
These observations suggest that an important role for FOXO is
maintaining viability of cancer initiating cells similar to that of normal
stem cells. How this can be reconciled with FOXOs function as tumor
suppressor is an important question that needs to be addressed.
10. Future perspectives
PI3K signaling remains one of the most intensely studied ﬁelds in
biology and here we have provided only a snap-shot of a few of the
1935D.E.A. Kloet, B.M.T. Burgering / Biochimica et Biophysica Acta 1813 (2011) 1926–1937many aspects of PI3K signaling, the PKB/FOXO switch. Initially, many
studies focussed on this switch from theperspective of a linearPI3K/PKB
pathwaydedicated to switch off FOXO function.However, it is becoming
clear that the PKB/FOXO switch is also regulated by cellular ROS levels in
a manner that may oppose PI3K/PKB. Understanding how ROS-
regulation tunes the PKB/FOXO switch is complicated by the observa-
tion that FOXOs themselves also regulate cellular ROS levels. Therefore,
the initial level and likely also the site of ROS formation becomes
relevant for the outcome. As ROS is also considered a driving force of
aging and the PKB/FOXO switch is important to the aging process,
understanding the details of FOXO regulation by ROS in the context of
PI3K signaling will become a task for the future. One possible role in
aging for the opposing actions of the ROS/JNK pathway versus the
insulin/PKB pathway, is to shift FOXOs from driving quiescence to
driving senescence, especially as the demand for tumor suppression
increases with age (see also Fig. 1). An important notion for comparing
FOXO and c-MYC function is that FOXOs and c-MYC functionally and
mechanistically antagonize each other at various levels. In disease,
especially cancer, recent results clearly show this antagonism to be
functionally relevant, but with respect to aging the consequence or
relevance of this antagonism remains to be investigated.References
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